Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background: Anaerobic bacterial resistance trends may vary across regions or institutions. Regional susceptibility patterns are pivotal in the empirical treatment of anaerobic infections. We determined the antimicrobial resistance patterns of clinically important anaerobic bacteria, including recently named or renamed anaerobes. Methods: A total of 521 non-duplicated clinical isolates of anaerobic bacteria were collected from a tertiary-care hospital in Korea between 2014 and 2016. Anaerobes were isolated from blood, body fluids, and abscess specimens. Each isolate was identified by conventional methods and by Bruker biotyper mass spectrometry (Bruker Daltonics, Leipzig, Germany) or VITEK matrix-assisted laser desorption ionization time-of-flight mass spectrometry (bioMérieux, Marcy-l’Étoile, France). Antimicrobial susceptibility was tested using the agar dilution method according to the CLSI guidelines. The following antimicrobials were tested: piperacillin-tazobactam, cefoxitin, cefotetan, imipenem, meropenem, clindamycin, moxifloxacin, chloramphenicol, tetracycline, and metronidazole. Results: Most Bacteroides fragilis isolates were susceptible to piperacillin-tazobactam, imipenem, and meropenem. The non-fragilis Bacteroides group (including B. intestinalis, B. nordii, B. pyogenes, B. stercoris, B. salyersiae, and B. cellulosilyticus) was resistant to meropenem (14%) and cefotetan (71%), and Parabacteroides distasonis was resistant to imipenem (11%) and cefotetan (95%). Overall, the Prevotella and Fusobacterium isolates were more susceptible to antimicrobial agents than the B. fragilis group isolates. Anaerobic gram-positive cocci exhibited various resistance rates to tetracycline (6–86%). Clostridioides difficile was highly resistant to penicillin, cefoxitin, imipenem, clindamycin, and moxifloxacin. Conclusions: Piperacillin-tazobactam, cefoxitin, and carbapenems are highly active β-lactam agents against most anaerobes, including recently named or renamed species.
Abstract
Background: Anaerobic bacterial resistance trends may vary across regions or institutions. Regional susceptibility patterns are pivotal in the empirical treatment of anaerobic infections. We determined the antimicrobial resistance patterns of clinically important anaerobic bacteria, including recently named or renamed anaerobes. Methods: A total of 521 non-duplicated clinical isolates of anaerobic bacteria were collected from a tertiary-care hospital in Korea between 2014 and 2016. Anaerobes were isolated from blood, body fluids, and abscess specimens. Each isolate was identified by conventional methods and by Bruker biotyper mass spectrometry (Bruker Daltonics, Leipzig, Germany) or VITEK matrix-assisted laser desorption ionization time-of-flight mass spectrometry (bioMérieux, Marcy-l’Étoile, France). Antimicrobial susceptibility was tested using the agar dilution method according to the CLSI guidelines. The following antimicrobials were tested: piperacillin-tazobactam, cefoxitin, cefotetan, imipenem, meropenem, clindamycin, moxifloxacin, chloramphenicol, tetracycline, and metronidazole. Results: Most Bacteroides fragilis isolates were susceptible to piperacillin-tazobactam, imipenem, and meropenem. The non-fragilis Bacteroides group (including B. intestinalis, B. nordii, B. pyogenes, B. stercoris, B. salyersiae, and B. cellulosilyticus) was resistant to meropenem (14%) and cefotetan (71%), and Parabacteroides distasonis was resistant to imipenem (11%) and cefotetan (95%). Overall, the Prevotella and Fusobacterium isolates were more susceptible to antimicrobial agents than the B. fragilis group isolates. Anaerobic gram-positive cocci exhibited various resistance rates to tetracycline (6–86%). Clostridioides difficile was highly resistant to penicillin, cefoxitin, imipenem, clindamycin, and moxifloxacin. Conclusions: Piperacillin-tazobactam, cefoxitin, and carbapenems are highly active β-lactam agents against most anaerobes, including recently named or renamed species.
참고문헌 (27)
- Schuetz AN, "Antimicrobial resistance and susceptibility testing of anaerobic bacteria", Clin Infect Dis, 59, pp.698~705 (2014)
- Hecht DW, "Anaerobes : antibiotic resistance, clinical significance, and the role of susceptibility testing", Anaerobe, 12, pp.115~121 (2006)
- 이양순, "Multicenter Study of Antimicrobial Susceptibility of Anaerobic Bacteria in Korea in 2012", Annals of Laboratory Medicine, 35(5), pp.479~486 (2015), 대한진단검사의학회
- Hastey CJ, "Changes in the antibiotic susceptibility of anaerobic bacteria from 2007–2009 to 2010–2012 based on the CLSI methodology", Anaerobe, 42, pp.27~30 (2016)
- CLSI, "Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. 8th ed. CLSI M11-A8", Clinical and Laboratory Standards Institute, ~ (2012)
- Lee K, "Antimicrobial resistance patterns of Bacteroides fragilis group organisms in Korea", Yonsei Med J, 39, pp.578~586 (1998)
- Lee Y, "Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea", Antimicrob Agents Chemother, 54, pp.3993~3997 (2010)
- 노경호, "Resistance Trends of Bacteroides fragilis Group Over an 8-Year Period, 1997-2004, in Korea", Annals of Laboratory Medicine, 29(4), pp.293~298 (2009), 대한진단검사의학회
- 임지숙, "Antimicrobial Susceptibility of Clinical Isolates of Bacteroides fragilis Group Organisms Recovered from 2009 to 2012 in a Korean Hospital", Annals of Laboratory Medicine, 35(1), pp.94~98 (2015), 대한진단검사의학회
- Wexler HM, "Bacteroides : the good, the bad, and the nitty-gritty", Clin Microbiol Rev, 20, pp.593~621 (2007)
- Sóki J, "Emergence and evolution of an international cluster of MDR Bacteroides fragilis isolates", J Antimicrob Chemother, 71, pp.2441~2448 (2016)
- Merchan C, "Multidrug-resistant Bacteroides fragilis bacteremia in a US resident : an emerging challenge", Case Rep Infect Dis, 2016, pp.3607125~ (2016)
- Sakamoto M, "Reclassification of Bacteroides distasonis, Bacteroides goldsteinii and Bacteroides merdae as Parabacteroides distasonis gen. nov., comb. nov., Parabacteroides goldsteinii comb. nov. and Parabacteroides merdae comb. nov", Int J Syst Evol Microbiol, 56, pp.1599~1605 (2006)
- Huys G, "Alloscardovia omnicolens gen. nov., sp. nov., from human clinical samples", Int J Syst Evol Microbiol, 57, pp.1442~1446 (2007)
- Downes J, "Bulleidia extructa gen. nov., sp. nov., isolated from the oral cavity", Int J Syst Evol Microbiol, 50, pp.979~983 (2000)
- Tee W, "Bacteremia due to Leptotrichia trevisanii sp. nov", Eur J Clin Microbiol Infect Dis, 20, pp.765~769 (2001)
- Rautio M, "Reclassification of Bacteroides putredinis (Weinberg et al., 1937) in a new genus Alistipes gen. nov., as Alistipes putredinis comb. nov., and description of Alistipes finegoldii sp. nov., from human sources", Syst Appl Microbiol, 26, pp.182~188 (2003)
- Song Y, "Alistipes onderdonkii sp. nov. and Alistipes shahii sp. nov., of human origin", Int J Syst Evol Microbiol, 56, pp.1985~1990 (2006)
- CLSI, "Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. 27th ed. CLSI M100", Clinical and Laboratory Standards Institute, ~ (2017)
- Yong D, "Evaluation of double-disk potentiation and disk potentiation tests using dipicolinic acid for detection of metallo-β-lactamase-producing Pseudomonas spp. and Acinetobacter spp", J Clin Microbiol, 50, pp.3227~3232 (2012)
- Snydman DR, "Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010–2012 with comparison to 2008–2009", Anaerobe, 43, pp.21~26 (2017)
- Sóki J, "Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey", Int J Antimicrob Agents, 28, pp.497~502 (2006)
- Papaparaskevas J, "Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece", J Antimicrob Chemother, 62, pp.137~141 (2008)
- Lee JH, "The changes of PCR ribotype and antimicrobial resistance of Clostridium difficile in a tertiary care hospital over 10 years", J Med Microbiol, 63, pp.819~823 (2014)
- Barberis C, "Antimicrobial susceptibility of clinical isolates of Actinomyces and related genera reveals an unusual clindamycin resistance among Actinomyces urogenitalis strains", J Glob Antimicrob Resist, 8, pp.115~120 (2017)
- Lee MR, "Clinical and microbiological characteristics of bacteremia caused by Eggerthella, Paraeggerthella and Eubacterium species at a university hospital in Taiwan, 2001-2010", J Clin Microbiol, 50, pp.2053~2055 (2012)
- Venugopal AA, "Risk and prognostic factors among patients with bacteremia due to Eggerthella lenta", Anaerobe, 18, pp.475~478 (2012)